Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6520339 | 1.00 | SHBG (0.43) | SHBGEPHX1TP53CA12CA1 | |
| SCHEMBL6525332 | 1.00 | SHBG (0.43) | SHBGEPHX1TP53CA12CA1 | |
| SCHEMBL6524219 | 1.00 | SHBG (0.43) | SHBGEPHX1TP53CA12CA1 | |
| SCHEMBL6524071 | 1.00 | SHBG (0.43) | SHBGEPHX1TP53CA12CA1 | |
| SCHEMBL6526132 | 1.00 | SHBG (0.43) | SHBGEPHX1TP53CA12CA1 | |
| SCHEMBL6527173 | 1.00 | SHBG (0.43) | SHBGEPHX1TP53CA12CA1 | |
| SCHEMBL19332953 | 1.00 | SHBG (0.43) | SHBGEPHX1TP53CA12CA1 | |
| SCHEMBL6520191 | 1.00 | SHBG (0.43) | SHBGEPHX1TP53CA12CA1 | |
| SCHEMBL6520108 | 0.97 | SHBG (0.39) | SHBGEPHX1TP53CA12CA1 | |
| SCHEMBL4653019 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233690-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2023-07-27 | — | — | US | disclosed |
| US-11312724-B2 | Spirocyclic tetrahydroquinazolines | ASCENTAGE PHARMA (SUZHOU) CO., LTD. | 2022-04-26 | — | — | US | disclosed |
| US-20210230174-A1 | SPIROCYCLIC TETRAHYDROQUINAZOLINES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-07-29 | — | — | US | disclosed |
| WO-2021139748-A1 | SPIROCYCLIC TETRAHYDROQUINAZOLINES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-07-15 | — | — | WO | disclosed |
| WO-2020198435-A1 | SMALL MOLECULE DEGRADERS OF STAT3 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-10-01 | — | — | WO | disclosed |
| US-20200115356-A1 | Modulation of Bacterial Quorum Sensing With Synthetic Ligands | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2020-04-16 | — | — | US | disclosed |
| US-20150004484-A1 | ORGANIC ELECTROLYTE AND ORGANIC ELECTROLYTE STORAGE BATTERY | JX NIPPON OIL & ENERGY CORPORATION (JP) | 2015-01-01 | — | — | US | disclosed |
| EP-2797153-A1 | ORGANIC ELECTROLYTE, AND ORGANIC ELECTROLYTE STORAGE BATTERY | JX Nippon Oil & Energy Corporation (JP) | 2014-10-29 | — | — | EP | disclosed |
| CN-104011928-A | Organic electrolyte, and organic electrolyte storage battery | JX NIPPON OIL & ENERGY CORP | 2014-08-27 | — | — | CN | disclosed |
| EP-0728145-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | Ciba-Geigy Japan Limited (JP) | 1996-08-28 | — | — | EP | disclosed |
| US-5493003-A | MIXTURES OF AMINES, AMIDES AND/OR ESTERS OF TETRACARBOXYLIC ACIDS HAVING AMIDO OR ESTER GROUPS SUBSTITUTED WITH CARBOXYL, SULFO, SILYL OR SILOXY GROUPS, ELECTRONICS | BASF LACKE + FARBEN AKTIENGESELLSCHAFT (DE) | 1996-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115356-A1 | Modulation of Bacterial Quorum Sensing With Synthetic Ligands | AHCYL1, EBPL, AIP | SHBG 282/4885EPHX1 3166/4885TP53 3185/4885 |
| US-20210230174-A1 | SPIROCYCLIC TETRAHYDROQUINAZOLINES | KRAS, NRAS, HRAS | SHBG 3242/4885EPHX1 1141/4885TP53 5/4885 |
| US-11312724-B2 | Spirocyclic tetrahydroquinazolines | KRAS, NRAS, HRAS | SHBG 3242/4885EPHX1 1141/4885TP53 5/4885 |
| US-20230233690-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | AR, SHBG, CYP19A1 | SHBG 2/4885EPHX1 3563/4885TP53 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.